Weekend Unlimited (CSE:YOLO) announces the harvest details related to the licensed tenant of Orchard Heights Growers, a Weekend Unlimited brand and property in Wenatchee, Washington.

“Orchard Heights’ licensed tenant, a pesticide free commercial cannabis Tier 3 producer / processor, conducted its first four days of harvest from October 30th to November 2nd, which produced over 1 ton of high quality, solar powered cannabis material, currently being dried,” noted Mr. Cody Corrubia, Weekend Unlimited Inc. President and CEO.


Harvest Highlights and Forward-Looking Production and Revenue Estimates:

  • Over the four days 4,000 pounds of bulk raw cannabis material was harvested from 10,000 sqft. of canopy
  • The material harvested is expected to produce over 50,000 grams of premium concentrate, 250,000 pre-rolls, or a combination of the two with premium concentrate infused pre-rolls*
  • Utilizing 1,408 plants and 10,000 sqft. of canopy it is anticipated that this proof of concept harvest will generate approximately $500,000 USD in revenue**

Assumptions and risks in respect to the forward-looking statements above:

*4000 lbs dries to 700 lbs with a yield of 18%, which equals 57,078 grams of concentrate. 700 lbs at 453 grams per pound will yield 317,100 1 g pre-rolls.

**Revenue estimate based upon average market prices of $10 per gram for live resin concentrate and $2 per gram for pre-rolls.

Risk of mold or other contamination in the flower would result in only concentrate being produced. In such a case, the amount produced may be less than projected.

“As a proof of concept crop, the 4,000 lbs of wet material harvested will be used to produce concentrates and pre-rolls. A quantity of the best product will be frozen and reserved for the launch of a premium Live Resin brand this winter,” added Mr. Corrubia.

The Orchard Heights property is being positioned as a B2B solution for independent growers looking for choice genetics, farming guidance, and processing and distribution solutions.

To serve this market, Orchard Heights is developing infrastructure, including a nursery with tissue culture technology and robotic automation, enabling the current operation to produce in excess of 2 million plants per year, which corresponds to over 10 million sqft. of canopy. The development of the infrastructure noted is underway and will be completed within six months at a cost of approximately $1 million USD.

With the expected consolidation and continued growth of a $1.3 Billion USD (https://www.tre.wa.gov/portfolio-item/washington-state-marijuana-revenues-and-health/) market in Washington State, Orchard Heights will have a primary focus on the B2B clone and nursery business, looking to capitalize on its agricultural systems and efficiency to be the leader in commercial commodity cannabis production.

For further information, please contact:
Telephone: 1 (236) 317-2812 – Toll free 1(888) 556-YOLO (9656)
E-mail: IR@weekendunlimited.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Click here to connect with Weekend Unlimited (CSE:YOLO) for an Investor Presentation. 

Source: www.accesswire.com

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less

Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model C. elegans

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

Keep reading... Show less